Global dissemination of extensively drug‐resistant carbapenemase‐producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control
Top Cited Papers
- 27 January 2015
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 277 (5) , 501-512
Abstract
The prevalence of carbapenem‐resistant Gram‐negative bacilli is on the rise worldwide, posing a major public health threat. Previously, this was mostly a problem in Pseudomonas and Acinetobacter, but during the last decade, carbapenem resistance has escalated in medically important species such as Klebsiella pneumoniae and Escherichia coli. In particular, the rising trend in E. coli is of concern, as this may lead to almost untreatable community‐acquired infections. Resistance is conferred by carbapenemases, which are beta‐lactamases that can breakdown essentially all beta‐lactams. Moreover, bacteria carrying these resistance determinants are often resistant to other treatment options, due to the frequent co‐acquisition of non‐beta‐lactam resistance genes located on the same mobile genetic elements. The detection of carbapenemase‐producing Enterobacteriaceae (CPE) is a challenge, because some carbapenemases produce relatively discrete levels of carbapenem resistance. Current clinical evidence for treatment guidance is limited and based on retrospective observational studies and case reports. Existing data support the use of combination therapy for treatment of severe infections caused by CPE. Combination regimens including colistin, carbapenems, tigecycline, aminoglycosides and fosfomycin have been used. Randomized controlled studies of combination regimens are ongoing and may help to determine the optimal therapy. Novel beta‐lactamase inhibitors may also have a role in future treatment of these infections. Strict infection control measures including isolation or cohort care of affected patients as well as contact tracing and active screening are needed to curb the spread of CPE. In this review, we provide a clinical perspective on the management of patients infected or colonized with CPE.Keywords
This publication has 59 references indexed in Scilit:
- Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic optionsClinical Microbiology and Infection, 2014
- Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination TherapyClinical Infectious Diseases, 2012
- Efficacy and safety of tigecycline: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2011
- Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence studyThe Lancet Infectious Diseases, 2011
- Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infectionsDiagnostic Microbiology and Infectious Disease, 2011
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infectionJournal of Antimicrobial Chemotherapy, 2010
- Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniaeJournal of Medical Microbiology, 2009
- Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strainsJournal of Antimicrobial Chemotherapy, 2009
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006